Voyager Therapeutics Q2 2024 Update
Ticker: VYGR · Form: 10-Q · Filed: Aug 6, 2024 · CIK: 1640266
Sentiment: neutral
Topics: 10-Q, biotech, collaboration, financials
TL;DR
Voyager Therapeutics has $54.5M cash, ongoing deals with Neurocrine & Novartis. Next steps TBD.
AI Summary
Voyager Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $54.5 million as of June 30, 2024. Key agreements mentioned include collaborations with Neurocrine Biosciences, Inc. and Novartis Pharma AG, with specific dates for these agreements ranging from 2019 to 2024.
Why It Matters
This filing provides insight into Voyager Therapeutics' financial health and ongoing strategic partnerships, which are crucial for its drug development pipeline.
Risk Assessment
Risk Level: medium — The company operates in the highly competitive and regulated biotechnology sector, with significant reliance on partnerships and clinical trial success.
Key Numbers
- $54.5M — Cash and Cash Equivalents (As of June 30, 2024)
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Filer
- Neurocrine Biosciences, Inc. (company) — Collaborator
- Novartis Pharma AG (company) — Collaborator
- $54.5 million (dollar_amount) — Cash and cash equivalents as of June 30, 2024
- Dr. Dinah Sah (person) — Related Party
FAQ
What is the total cash and cash equivalents reported by Voyager Therapeutics as of June 30, 2024?
Voyager Therapeutics reported $54,472,113 in cash and cash equivalents as of June 30, 2024.
When was the Neurocrine Collaborative Agreement entered into?
The Neurocrine Collaborative Agreement was entered into in 2019.
What is the nature of the agreement with Novartis Pharma AG?
Voyager Therapeutics has a collaboration agreement with Novartis Pharma AG, referred to as the Novartis Collaboration Agreement 2023, which was effective as of December 28, 2023.
Are there any significant subsequent events reported after the reporting period?
Yes, the filing indicates subsequent events occurring between August 1, 2024, and August 31, 2024.
What is the company's fiscal year end?
Voyager Therapeutics' fiscal year ends on December 31.
Filing Stats: 4,426 words · 18 min read · ~15 pages · Grade level 18.1 · Accepted 2024-08-06 16:01:34
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value VYGR Nasdaq Global Select
Filing Documents
- vygr-20240630x10q.htm (10-Q) — 1547KB
- vygr-20240630xex10d1.htm (EX-10.1) — 26KB
- vygr-20240630xex31d1.htm (EX-31.1) — 13KB
- vygr-20240630xex31d2.htm (EX-31.2) — 13KB
- vygr-20240630xex32d1.htm (EX-32.1) — 10KB
- vygr-20240630x10q006.jpg (GRAPHIC) — 76KB
- 0001558370-24-011073.txt ( ) — 6728KB
- vygr-20240630.xsd (EX-101.SCH) — 41KB
- vygr-20240630_cal.xml (EX-101.CAL) — 48KB
- vygr-20240630_def.xml (EX-101.DEF) — 175KB
- vygr-20240630_lab.xml (EX-101.LAB) — 361KB
- vygr-20240630_pre.xml (EX-101.PRE) — 284KB
- vygr-20240630x10q_htm.xml (XML) — 1201KB
Forward-Looking Statements
Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "contemplate," "anticipate," "goals," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: our plans to develop and commercialize our product candidates based on adeno-associated virus, or AAV, gene therapy and our proprietary antibodies; our ability to continue to develop our proprietary gene therapy platform technologies, including our TRACER TM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) discovery platform and our vectorized antibody platform, our proprietary antibody program, and our gene therapy and vectorized antibody programs; our ability to identify and optimize product candidates and proprietary AAV capsids; our strategic collaborations and licensing agreements with, and funding from, our collaboration partners Neurocrine Biosciences, Inc. and Novartis Pharma AG, and our licensee Alexion, AstraZeneca Rare Di
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 5 CONDENSED CONSOLIDATED BALANCE SHEETS 5 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) Income 6 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY 7 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 8 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 9 ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 18 ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 36 ITEM 4.
CONTROLS AND PROCEDURES
CONTROLS AND PROCEDURES 36
OTHER INFORMATION
PART II. OTHER INFORMATION ITEM 1.
LEGAL PROCEEDINGS
LEGAL PROCEEDINGS 37 ITEM 1A.
RISK FACTORS
RISK FACTORS 37 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS ITEM 5. OTHER INFORMATION 37 ITEM 6. EXHIBITS 37
SIGNATURES
SIGNATURES 39 4 Table of Contents
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION Voyager Therapeutics, Inc. Condensed Consolidated Balance Sheet s (amounts in thousands, except share and per share data) (unaudited) June 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 76,127 $ 68,802 Marketable securities, current 294,894 162,073 Accounts receivable 1,702 80,150 Related party collaboration receivable 1,549 3,341 Prepaid expenses and other current assets 7,298 5,318 Total current assets 381,570 319,684 Property and equipment, net 16,267 16,494 Deposits and other non-current assets 2,874 1,593 Operating lease, right-of-use assets 35,514 13,510 Total assets $ 436,225 $ 351,281 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,605 $ 1,604 Accrued expenses 10,273 16,823 Other current liabilities 6,736 3,200 Deferred revenue, current 20,516 42,881 Total current liabilities 40,130 64,508 Deferred revenue, non-current 19,473 32,359 Other non-current liabilities 41,205 18,094 Total liabilities 100,808 114,961 Commitments and contingencies (see note 7) Stockholders' equity: Preferred stock, $ 0.001 par value: 5,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023 — — Common stock, $ 0.001 par value: 120,000,000 shares authorized at June 30, 2024 and December 31, 2023; 54,472,113 and 44,038,333 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 54 44 Additional paid-in capital 618,538 497,506 Accumulated other comprehensive loss ( 522 ) ( 48 ) Accumulated deficit ( 282,653 ) ( 261,182 ) Total stockholders' equity 335,417 236,320 Total liabilities and stockholders' equity $ 436,225 $ 351,281 The accompanying notes are an integral part of these condensed c onsolidated financial statements. 5 Table of